In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly, Boehringer Ingelheim in duloxetine co-promotion

Executive Summary

Boehringer Ingelheim and Eli Lilly will co-promote worldwide (excluding Japan) duloxetine for female stress urinary incontinence (SUI); the partners will also co-promote Lilly's depression drug duloxetine HCl under the brand name Cymbalta worldwide outside the US--where Lilly already has a co-promotion agreement with Quintiles division Innovex--and excluding Japan.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies